弃了!百时美施贵宝终止KRAS G12D项目

新浪财经
07 Mar

2025年3月5日,据外媒消息, 百时美施贵宝 (BMS)已放弃了此前收购的KRAS G12D抑制剂MRTX1133项目。在肿瘤治疗领域,KRAS G12D抑制剂一直是研究的热点。KRAS G12D是一种在多种癌症中常见的突变类型,尤其在胰腺癌中,约80%的患者存在KRAS突变,且大部分为G12D突变。这使得KRAS G12D成为胰腺癌治疗中一个十分有前景的治疗靶点。寄予厚望的KRAS项目此前被...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10